Olivieri O, Friso S, Manzato F, Grazioli S, Bernardi F, Lunghi B, Girelli D, Azzini M, Brocco G, Russo C, Corrocher R
Institute of Medical Pathology, University of Verona, Italy.
Contraception. 1996 Sep;54(3):149-52. doi: 10.1016/s0010-7824(96)00169-2.
Resistance to activated protein C (APC-R) is at present considered the most frequent laboratory abnormality in patients with deep vein thrombosis. An increased risk for venous thrombosis is associated with the use of oral contraceptives (OCs). We recently described a statistically significant association between APC-R status and oral contraceptives use in a healthy group of women. We re-evaluated 50 healthy women taking low-dose combination OCs in order to consider a possible correlation between the APC sensitivity ratio (APC-SR) and different oral contraceptive formulations. Seven women showed an APC ratio < or = 2 (APC-resistant). Only one of the seven women was found to be heterozygous for Leiden factor V mutation. We observed no significant differences between normally sensitive and APC-resistant women in terms of duration of OC use, amount of estrogenic or progestogenic dose, or type of formulation. We conclude that APC-resistance associated with oral contraceptives use seems to occur only in predisposed subjects (in our results, about 12% of the healthy population).
目前，对活化蛋白C的抵抗（APC-R）被认为是深静脉血栓形成患者中最常见的实验室异常情况。使用口服避孕药（OCs）会增加静脉血栓形成的风险。我们最近在一组健康女性中描述了APC-R状态与口服避孕药使用之间具有统计学意义的关联。我们重新评估了50名服用低剂量复方OCs的健康女性，以探讨活化蛋白C敏感率（APC-SR）与不同口服避孕药配方之间可能存在的相关性。7名女性的APC比值≤2（对活化蛋白C抵抗）。这7名女性中只有1名被发现为莱顿V因子突变杂合子。在正常敏感和对活化蛋白C抵抗的女性之间，我们未观察到在口服避孕药使用时长、雌激素或孕激素剂量或配方类型方面存在显著差异。我们得出结论，与口服避孕药使用相关的对活化蛋白C抵抗似乎仅发生在易感人群中（在我们的研究结果中，约占健康人群的12%）。
